FPT-CORPORATION
Global leading IT firm FPT today announced a comprehensive strategic partnership with NVIDIA, aiming to offer a one-stop shop for AI & Cloud consisting of AI products, GPU infrastructure, tech experts, and domain expertise for clients in Vietnam and all FPT’s presence areas. This endeavor will be attained by establishing AI factories for AI research and development in the region, expanding advanced AI and cloud capabilities on a global scale, and fostering a future-ready workforce in technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422007290/en/
The MoU signing ceremony took place in Hanoi, Vietnam, with the participation of FPT and NVIDIA senior executives (Photo: Business Wire)
FPT plans to invest USD 200 million in building an AI factory that will serve as a sovereign cloud. These will feature NVIDIA’s latest technologies, including NVIDIA AI Enterprise software and frameworks and NVIDIA H100 Tensor Core GPUs.
This initiative is a critical part of FPT’s strategy in reinforcing AI research and development, creating AI applications and solutions with a focus on generative AI, autonomous driving, and green transformation for sustainability. This empowers FPT to realize the vision of transforming Vietnam into an AI nation and accelerating the adoption of AI applications in Asia, including but not limited to Vietnam, Japan, and Korea.
AI Factory will provide cloud GPU services to accompany FPT's corporate customers globally to access the most core resources to improve research capacity, accelerate the speed of AI applications, especially Generative AI, and achieve breakthroughs in improving productivity and customer experience.
At the same time, it helps FPT accelerate the construction and development of AI platforms and applications with higher value for customers in all industries.
As part of the collaboration, FPT has joined the NVIDIA Partner Network as a Service Delivery Partner and aims to become a Global Systems Integrator, leveraging the full potential of NVIDIA's cutting-edge products and technologies to develop bespoke cloud services, hardware, software, and most importantly, generative AI solutions. Prioritizing three key verticals, including automotive, manufacturing, banking, financial services, and insurance, FPT will offer end-to-end generative AI services, empowering businesses to unlock the next level of productivity and automation. The integrations will enhance FPT’s AI Labs while introducing new software frameworks.
Additionally, FPT’s education group will work to strengthen the AI workforce by incorporating NVIDIA’s programs into educational curriculum and activities, training programs, and lab facilities at both university and high school levels, aiming to reach at least 30,000 students within 5 years.
FPT further intends to collaborate with NVIDIA on opportunities to develop cloud gaming with NVIDIA GeForce NOW in Vietnam.
Speaking at the signing ceremony, Dr. Truong Gia Binh, FPT Corporation Chairman and Founder, affirmed: “FPT is committed to Digital transformation, AI, Cloud, and Education. FPT strives to enhance our R&D competence and establish a comprehensive platform for state-of-the-art products and services built on AI and Cloud that exceeds global demands, working to achieve its vision to turn Vietnam into an AI hub of the world through collaboration with NVIDIA in technology, business development, and training.”
Keith Strier, NVIDIA Vice President of Worldwide AI Initiative, said: “By accelerating innovation in healthcare, agriculture, climate, manufacturing, and more, AI has the potential to improve lives and strengthen the economies of every nation. FPT is working with NVIDIA to empower organizations across Vietnam to drive transformation, helping the country become an AI nation.”
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422007290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom